摘要
目的研究步长稳心颗粒治疗心律失常的疗效及安全性。方法将150例心律失常患者随机分为治疗组和对照组,每组75例。治疗组给予步长稳心颗粒1包(9g),口服,3次/d;对照组常规口服盐酸普罗帕酮片100mg,3次/d,均4周1个疗程。观察2组临床症状及24h动态心电图的变化,以评估其疗效。结果治疗组疗效总有效率明显高于对照组(82.67%vs64.00%,χ2=6.682,P<0.01);心电图变化的总有效率明显高于对照组(76.00%vs58.67%,χ2=5.122,P=0.024)。房颤疗效2组比较差异无统计学意义(56.52%vs61.90%,χ2=0.132,P=0.717)。结论步长稳心颗粒对治疗房性早搏、室性早搏有一定疗效,安全性好,但对房颤的疗效并不优于普罗帕酮。
Objective To study the anti-arrhythmia effect and safety of Wenxinkeli for the patients with cardiac arrhythmia.Methods 150 patients with cardiac arrhythmia were divided into therapy group and control group at random,75 in every group.Therapy group took Wenxinkeli 9 g,3 times a day,and control group took Propafenone 100 mg,3 times a day,4 weeks for one period of treatment.The curative effect＇s was assessed by the clinical symptoms and the change of 24 hours dynamic electrocardiogram.Results The clinical total effective rate of therapy group was higher than that of control group（82.67% vs 64.00%,χ2=6.682,P=0.010）,and The ECG total effective rate of therapy group was higher than that of control group（76.00% vs 58.67%,χ2=5.122,P=0.024）.But there was no significant difference between two groups in the ECG total effective rate on artrial fibrillation （56.52% vs 61.90%,χ2=0.132,P=0.717）.Conclusion As other drug for cardiac arrhythmia,Wenxinkeli could improve the therapeutic effect in the treatment of atrial or ventricular premature beat,which should be safe and better than Propafenone.But the therapeutic effect of Wenxinkeli on atrial fibrillation was not superior to Propafenone.
出处
《江西医学院学报》
CAS
2009年第9期52-54,共3页
Acta Academiae Medicinae Jiangxi
